Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Pluri Inc PLUR

Healthcare Biotechnology
Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. It develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and immunotherapy platform. The company’s product candidates include PLX-PAD, that is composed of maternal mesenchymal stromal cells originating from the placenta for the treatment of various indications, such as acute muscle injuries following hip fracture, acute respiratory distress syndrome due to coronavirus Disease (COVID-19), peripheral artery disease, intermittent claudication, and critical limb ischemia; PLX-R18, composed of fetal MSC like cells originating from the placenta for the treatment of hematopoietic complications of the H-ARS, and is in Phase I clinical trial to treat hematopoietic cell transplantation; and allogeneic MAIT cell therapy platform. It ...


NDAQ:PLUR - Post by User

Pluri Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(76)
•••
  • lucaM1X
Post by lucaM1on May 09, 2022 9:25am
111 Views
Post# 34666381

$PSTI among the 5 Biotech Penny Stocks Redditors Love

$PSTI among the 5 Biotech Penny Stocks Redditors LovePluristem Therapeutics Inc. (NASDAQ:PSTI) is a biotech firm specializing in cell therapeutic products and related technologies. In early January, the stock jumped more than 30% after the company announced that it would be partnering with Tnuva Group, one of the largest food producers in Israel, for the development and launch of cultured cell-based products for the food industry. The latter is expected to invest over $7 million in the project with the option to invest double this amount within twelve months. 


Some other projects that Pluristem Therapeutics Inc. (NASDAQ:PSTI) is working on include research related to the potential of PLX cell therapies in preventing and treating medical conditions caused during space missions.
Among the hedge funds being tracked by Insider Monkey, New York-based investment firm ARK Investment Management is a leading shareholder in Pluristem Therapeutics Inc. (NASDAQ:PSTI), with 1 million shares worth more than $1.5 million. 

https://www.insidermonkey.com/blog/5-biotech-penny-stocks-redditors-love-1041208/2/
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities